NASDAQ:PSTI

Pluristem Therapeutics Competitors

$4.73
-0.05 (-1.05 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.70
Now: $4.73
$4.96
50-Day Range
$4.48
MA: $5.49
$7.22
52-Week Range
$4.30
Now: $4.73
$13.29
Volume226,100 shs
Average Volume733,700 shs
Market Capitalization$149.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53

Competitors

Pluristem Therapeutics (NASDAQ:PSTI) Vs. MGTX, TARS, CGEN, AGEN, SLDB, and PSTX

Should you be buying PSTI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Pluristem Therapeutics, including MeiraGTx (MGTX), Tarsus Pharmaceuticals (TARS), Compugen (CGEN), Agenus (AGEN), Solid Biosciences (SLDB), and Poseida Therapeutics (PSTX).

Pluristem Therapeutics (NASDAQ:PSTI) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pluristem Therapeutics and MeiraGTx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluristem Therapeutics$20,000.007,456.61$-29,150,000.00N/AN/A
MeiraGTx$13.29 million44.46$-54,750,000.00($1.65)-8.09

Pluristem Therapeutics has higher earnings, but lower revenue than MeiraGTx.

Risk & Volatility

Pluristem Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

12.0% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of MeiraGTx shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Comparatively, 16.5% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pluristem Therapeutics and MeiraGTx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pluristem TherapeuticsN/A-86.51%-68.23%
MeiraGTx-283.20%-29.14%-17.49%

Analyst Recommendations

This is a breakdown of current ratings for Pluristem Therapeutics and MeiraGTx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pluristem Therapeutics01302.75
MeiraGTx00403.00

Pluristem Therapeutics currently has a consensus target price of $9.75, indicating a potential upside of 106.13%. MeiraGTx has a consensus target price of $33.00, indicating a potential upside of 147.19%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Pluristem Therapeutics.

Summary

MeiraGTx beats Pluristem Therapeutics on 8 of the 12 factors compared between the two stocks.

Pluristem Therapeutics (NASDAQ:PSTI) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pluristem Therapeutics and Tarsus Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluristem Therapeutics$20,000.007,456.61$-29,150,000.00N/AN/A
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Pluristem Therapeutics.

Institutional and Insider Ownership

12.0% of Pluristem Therapeutics shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pluristem Therapeutics and Tarsus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pluristem TherapeuticsN/A-86.51%-68.23%
Tarsus PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Pluristem Therapeutics and Tarsus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pluristem Therapeutics01302.75
Tarsus Pharmaceuticals00413.20

Pluristem Therapeutics currently has a consensus target price of $9.75, indicating a potential upside of 106.13%. Tarsus Pharmaceuticals has a consensus target price of $37.25, indicating a potential upside of 30.43%. Given Pluristem Therapeutics' higher possible upside, equities research analysts clearly believe Pluristem Therapeutics is more favorable than Tarsus Pharmaceuticals.

Summary

Tarsus Pharmaceuticals beats Pluristem Therapeutics on 5 of the 9 factors compared between the two stocks.

Pluristem Therapeutics (NASDAQ:PSTI) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pluristem Therapeutics and Compugen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluristem Therapeutics$20,000.007,456.61$-29,150,000.00N/AN/A
Compugen$17.80 million32.36$-27,340,000.00($0.43)-19.58

Compugen has higher revenue and earnings than Pluristem Therapeutics.

Risk & Volatility

Pluristem Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500.

Institutional and Insider Ownership

12.0% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Compugen shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pluristem Therapeutics and Compugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pluristem TherapeuticsN/A-86.51%-68.23%
CompugenN/A-26.98%-23.28%

Analyst Recommendations

This is a breakdown of current ratings for Pluristem Therapeutics and Compugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pluristem Therapeutics01302.75
Compugen00703.00

Pluristem Therapeutics currently has a consensus target price of $9.75, indicating a potential upside of 106.13%. Compugen has a consensus target price of $20.2857, indicating a potential upside of 140.92%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Pluristem Therapeutics.

Summary

Compugen beats Pluristem Therapeutics on 9 of the 11 factors compared between the two stocks.

Pluristem Therapeutics (NASDAQ:PSTI) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pluristem Therapeutics and Agenus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluristem Therapeutics$20,000.007,456.61$-29,150,000.00N/AN/A
Agenus$150.05 million3.79$-107,660,000.00($0.80)-3.48

Pluristem Therapeutics has higher earnings, but lower revenue than Agenus.

Risk & Volatility

Pluristem Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.

Institutional and Insider Ownership

12.0% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 53.4% of Agenus shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pluristem Therapeutics and Agenus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pluristem TherapeuticsN/A-86.51%-68.23%
Agenus-192.56%N/A-97.02%

Analyst Recommendations

This is a breakdown of current ratings for Pluristem Therapeutics and Agenus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pluristem Therapeutics01302.75
Agenus00303.00

Pluristem Therapeutics currently has a consensus target price of $9.75, indicating a potential upside of 106.13%. Agenus has a consensus target price of $8.00, indicating a potential upside of 186.74%. Given Agenus' stronger consensus rating and higher possible upside, analysts clearly believe Agenus is more favorable than Pluristem Therapeutics.

Summary

Pluristem Therapeutics beats Agenus on 6 of the 11 factors compared between the two stocks.

Pluristem Therapeutics (NASDAQ:PSTI) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pluristem Therapeutics and Solid Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluristem Therapeutics$20,000.007,456.61$-29,150,000.00N/AN/A
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-1.79

Pluristem Therapeutics has higher revenue and earnings than Solid Biosciences.

Risk & Volatility

Pluristem Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Institutional and Insider Ownership

12.0% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of Solid Biosciences shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Comparatively, 31.2% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pluristem Therapeutics and Solid Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pluristem TherapeuticsN/A-86.51%-68.23%
Solid BiosciencesN/A-194.22%-140.40%

Analyst Recommendations

This is a breakdown of current ratings for Pluristem Therapeutics and Solid Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pluristem Therapeutics01302.75
Solid Biosciences01402.80

Pluristem Therapeutics currently has a consensus target price of $9.75, indicating a potential upside of 106.13%. Solid Biosciences has a consensus target price of $12.40, indicating a potential upside of 138.00%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Pluristem Therapeutics.

Pluristem Therapeutics (NASDAQ:PSTI) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pluristem Therapeutics and Poseida Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluristem Therapeutics$20,000.007,456.61$-29,150,000.00N/AN/A
Poseida TherapeuticsN/AN/AN/A($6.86)-1.30

Poseida Therapeutics has lower revenue, but higher earnings than Pluristem Therapeutics.

Institutional and Insider Ownership

12.0% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of Poseida Therapeutics shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Comparatively, 19.0% of Poseida Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pluristem Therapeutics and Poseida Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pluristem TherapeuticsN/A-86.51%-68.23%
Poseida TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Pluristem Therapeutics and Poseida Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pluristem Therapeutics01302.75
Poseida Therapeutics00303.00

Pluristem Therapeutics currently has a consensus target price of $9.75, indicating a potential upside of 106.13%. Poseida Therapeutics has a consensus target price of $25.00, indicating a potential upside of 180.90%. Given Poseida Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Poseida Therapeutics is more favorable than Pluristem Therapeutics.

Summary

Poseida Therapeutics beats Pluristem Therapeutics on 6 of the 7 factors compared between the two stocks.


Pluristem Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.35-3.3%$590.92 million$13.29 million-9.47
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.56-1.2%$585.57 millionN/A0.00Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.42-0.0%$576.10 million$17.80 million-22.76Analyst Revision
Agenus logo
AGEN
Agenus
1.6$2.78-0.4%$570.05 million$150.05 million-2.55
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.21-3.1%$556.83 millionN/A-2.53Gap Down
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.90-0.6%$552.76 millionN/A-1.30Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.48-2.5%$530.64 millionN/A-5.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.60-3.6%$490.08 million$22.24 million-4.28
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$13.23-5.1%$474.60 millionN/A0.00
AVROBIO logo
AVRO
AVROBIO
1.7$11.32-2.5%$471.16 millionN/A-3.43
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.25-1.5%$466.41 millionN/A-8.20
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.10-1.4%$445.46 million$4.36 million-3.18Analyst Upgrade
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.78-6.6%$443.95 million$147.87 million-3.25News Coverage
Opthea logo
OPT
Opthea
1.5$9.66-1.2%$419.80 millionN/A0.00Lockup Expiration
News Coverage
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.51-6.4%$397.95 millionN/A0.00
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.66-1.0%$380.70 millionN/A0.00
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$2.19-2.7%$380.20 million$8.15 million-1.75
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.27-2.3%$348.11 million$250,000.00-3.31
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.49-6.2%$340.69 millionN/A0.00Lockup Expiration
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.26-2.1%$336.50 million$96.12 million-12.53Analyst Revision
Surface Oncology logo
SURF
Surface Oncology
1.4$7.95-2.8%$331.74 million$15.36 million-12.05Analyst Report
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.60-3.4%$293.14 million$2.91 million-1.95
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$8.40-1.8%$284.77 millionN/A-3.46
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$2.03-1.0%$283.79 million$4.13 million-4.51
PDL BioPharma logo
PDLI
PDL BioPharma
0.8$2.47-9.3%$282.14 million$54.76 million-2.19High Trading Volume
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.76-0.7%$258.92 millionN/A-7.85
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$10.57-0.9%$228.50 millionN/A0.00Gap Down
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.76-6.3%$213.44 million$29.35 million-2.05
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$6.16-2.9%$197.28 millionN/A-3.85
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.83-3.2%$189.64 millionN/A-5.48
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.41-3.6%$188.54 million$2.45 million-2.07
Genfit logo
GNFT
Genfit
1.3$4.62-0.4%$179.53 million$45.88 million-2.35
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.76-0.2%$179.23 million$104.39 million-2.90
INmune Bio logo
INMB
INmune Bio
1.5$11.77-3.2%$175.76 millionN/A-12.13
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.95-3.3%$167.87 millionN/A0.00
Axcella Health logo
AXLA
Axcella Health
1.6$4.34-5.5%$163.58 millionN/A-2.02
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.28-2.2%$163.30 millionN/A-7.66
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.02-4.8%$156.80 millionN/A-2.82
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.32-0.5%$151.58 million$32.12 million-87.08
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.79-1.6%$143.85 millionN/A-1.73
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.85-0.5%$142.89 million$2.33 million0.00Gap Up
Dyadic International logo
DYAI
Dyadic International
1.3$5.17-1.4%$142.45 million$1.68 million-15.21
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.66-1.1%$142.36 millionN/A-1.83Analyst Revision
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$13.24-0.3%$135.39 millionN/A0.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$8.62-4.2%$133.43 million$3 million-2.77
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.65-0.0%$130.38 millionN/A-3.48
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.08-2.5%$111.91 million$23.05 million-1.81
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.30-4.3%$110.50 million$20.92 million-1.32
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.25-1.3%$107.60 million$140,000.000.00
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.30-3.1%$73.94 millionN/A-1.03
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.